Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study
Cassidy A. Gutner(Boston University), Maggie Czarnogorski, Thomas A. Lutz(ZHAW Zurich University of Applied Sciences), Rebecca DeMoor(GlaxoSmithKline (United States)), Jenny Scherzer, Annemiek de Ruiter(ViiV Healthcare (Spain)), Nicola Barnes(University of Portsmouth), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Leïla Belkhir, Monica Hadi(EVRAZ (United Kingdom)), Beatríz Hernández(ViiV Healthcare (Spain)), M. Pascual-Bernaldez(ViiV Healthcare (Spain)), Rekha Trehan(ViiV Healthcare (United Kingdom)), Marc van der Valk(Academic Medical Center), Perry Mohammed(ViiV Healthcare (United Kingdom)), Emma Low(EVRAZ (United Kingdom)), Eliette Jeanmaire(Centre Hospitalier Régional et Universitaire de Nancy), Nick Sevdalis(National University of Singapore), Mounir Ait‐Khaled(ViiV Healthcare (United Kingdom)), Savita Bakhshi Anand(EVRAZ (United Kingdom))
Journal of the International Association of Providers of AIDS Care (JIAPAC)
January 1, 2024
Cited by 14
Related Papers
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395